Posted by Michael Wonder on 24 Oct 2018
Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
24 October 2018 - This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C.
PHARMAC provided an update on this proposal on 27 August 2018, which noted that a listing date of 1 October 2018 was not achievable and that we did not have a firm timeframe for when a decision would be made.
This update is to advise that the proposal to list glecaprevir and pibrentasvir (Maviret) is still being reviewed by PHARMAC and that the product will not be listed before the end of the 2018 calendar year.
